(70ec) Formulation of Large Hollow Nanoparticles Aggregates as Potential Carriers of Inhaled Drug Nanoparticles

Inhaled dry powder aerosols are effective therapeutic carriers for target-specific treatments of various pulmonary diseases, such as asthma, cystic fibrosis, chronic pulmonary infections, lung cancer, etc. Owing to high permeability of human lungs epithelia toward therapeutic agents, inhaled dry powder aerosols also serve as an attractive alternative to oral and parenteral routes for systemic delivery of biotherapeutic agents i.e. insulin, growth hormone, proteins, peptides, etc. that currently can only be delivered through gastrointestinal tract or parenterally by either intravenous or intramuscular injections.1 The effectiveness of inhaled aerosol drug delivery largely depends on its ability to provide a controlled and sustained release of the therapeutic agents once they reach the lungs. Furthermore, the inhaled aerosols must be able to escape the natural clearance mechanisms in the lungs i.e. mucociliary and phagocytic clearances until the drugs have been effectively delivered. In addition, the inhaled aerosols must possess a very narrow range of aerodynamic diameters (1 References:

1) Edwards D.A. Delivery of Biological Agents by Aerosols. AIChE Journal. 2002, 48 (1), 2-6. 2) Hardy J.G.; Chadwick T.S. Sustained Release of Drug Delivery to the Lungs. Clin. Pharmacokinetics. 2000, 39, 1-4. 3) Edwards D.A.; Hanes J.; Caponetti G.; Hrkach J.; Ben-Jebria A.; Eskew M.; Mintzes J.; Deaver D.; Lotan N.; Langer R. Large Porous Particles for Pulmonary Drug Delivery. Science. 1997, 276, 1868-1871. 4) Tsapis N.; Bennet D.; Jackson B.; Weitz D.A.; Edwards D.A. Trojan Particles: Large Porous Carriers of Nanoparticles for Drug Delivery. Proceeding of National Academy of Sciences. 2002, 99 (19), 12001-12005. 5) Sham J.; Zhang Y.; Finlay W.; Roa W.; LÖbenberg R. Formulation and Characterization of Spray-Dried Powders Containing Nanoparticles for Aerosol Delivery to the Lung. Intl. J. Pharmaceutics. 2004, 269, 457-467. 6) Chattopadhyay P.; Gupta R.B. Production of Antibiotic Nanoparticles Using Supercritical CO2 as Antisolvent with Enhanced Mass Transfer. Ind. Eng. Chem. Res. 2001, 40, 3530-3539. 7) Shargel L.; Yu A.B. Applied Biopharmaceutics & Pharmacokinetics 4th Edition; McGraw Hill: New York, 1999. 8) Lee J.H. Drug Nano and Microparticles Processed into Solid Dosage Forms: Physical Properties. J. Pharmaceutical Sciences. 2003, 92 (10), 2057-2068.